ABBISKO-B (02256) announced that its novel selective CDK4 inhibitor ABSK192 monotherapy and combination therapy preclinical research results were presented at the 2026 ENA Conference
ABBISKO-B (02256) announced that its subsidiary, Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Therapeutics), announced that the preclinical research results of its independently developed novel selective CDK4 inhibitor ABSK192 were presented in poster format at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2026 (2026 ENA Conference).
ABBISKO-B (02256) announced that its subsidiary Shanghai Abbisko Biomedical Technology Co., Ltd. (Abbisko Therapeutics) announced that the preclinical research results of its independently developed novel selective CDK4 inhibitor ABSK192 were presented in poster form at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2026 (2026 ENA Conference). This study was selected for the Late-Breaking Abstracts (LBA) program, and Dr. Zhang Nannan, Senior Director of Translational Medicine and Biomarker Research at Abbisko Therapeutics, presented on-site the monotherapy activity and broad combination therapy potential of ABSK192 in HR+/HER2- breast cancer models.
Related Articles

HK Stock Market Move | CATHAY PAC AIR (00293) rises over 3%; October passenger traffic up 4% year-on-year; JP Morgan bullish on its market share and yield advantages.

HK Stock Market Move | IMPACT THERAP-B (07630) rose over 15% against the market trend as Senaparib received EU approval for first-line maintenance treatment of ovarian cancer in the all-comer population.

UBS: Cuts CHINA RES MIXC (01209) target price to HK$52, maintains "Buy" rating.
HK Stock Market Move | CATHAY PAC AIR (00293) rises over 3%; October passenger traffic up 4% year-on-year; JP Morgan bullish on its market share and yield advantages.

HK Stock Market Move | IMPACT THERAP-B (07630) rose over 15% against the market trend as Senaparib received EU approval for first-line maintenance treatment of ovarian cancer in the all-comer population.

UBS: Cuts CHINA RES MIXC (01209) target price to HK$52, maintains "Buy" rating.






